

**SAMPLE TYPE:** Serum

**DOCTOR / PATIENT ID:**

**PAGES:** 1 of 1

**PRACTITIONER**

[Redacted]

**PATIENT**

**Name:** REPORT, SAMPLE

[Redacted]

TEST	RESULT			
	IN RANGE (Normal)	EQUIVOCAL*	OUT OF RANGE	REFERENCE (ELISA Index)
<b>Array 2 – Intestinal Antigenic Permeability Screen</b>				
Actomyosin IgA **	10.63			0.0-20
Occludin/Zonulin IgG	0.45			0.2-1.5
Occludin/Zonulin IgA	0.24			0.1-1.8
Occludin/Zonulin IgM	0.62			0.1-2.1
Lipopolysaccharides (LPS) IgG	0.81			0.1-1.6
Lipopolysaccharides (LPS) IgA	0.29			0.1-1.8
Lipopolysaccharides (LPS) IgM	0.55			0.1-2.0

\* Reference ranges are calculated based on the mean  $\pm 2$  standard deviations (SD). Results  $> 1$  SD, and  $< 2$  SDs above the mean are considered to be equivocal. An equivocal result represents the range between negative and suspicious low positive results. Results  $> 2$  SDs are considered out of range, and positive.

Mark G. Kartub, M.D., Medical Director

\*\*Actomyosin IgA results were obtained utilizing the INOVA Diagnostics Inc. QUANTA LITE Actin IgA kit.  $\leq 20$  units is considered a negative result, 20.1-24.9 units is an equivocal result and  $\geq 25$  units is a positive result, Actin values obtained from different manufacturer's assay methods may not be used interchangeably. The magnitude of the reported IgA levels cannot be correlated to an endpoint titer.

Cyrex Laboratories is certified under the Clinical Laboratory Improvement Amendments of 1988 ("CLIA") as qualified to perform high-complexity clinical testing. Test result data on its own does not constitute a diagnosis. Only a physician or qualified healthcare professional should interpret the significance of a clinical lab test or make a diagnosis. This test was developed and its performance characteristics determined by Cyrex Laboratories, LLC. The names and titles of tests and arrays are for reference purposes only.